|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?显示文摘Pancreatic ductal adenocarcinoma(PDAC)is one of the deadliest cancers,mostly due to its resistance to treatment.Of these,checkpoint inhibitors(CPI)are inefficient when used as monotherapy,except in the case of a rare subset of tumors harboring microsatellite instability(<2%).This inefficacy mainly resides in the low immunogenicity and non-inflamed phenotype of PDAC.The abundant stroma generates a hypoxic microenvironment and drives the recruitment of immunosuppressive cells through cancerassociated-fibroblast activation and transforming growth factorβsecretion.Several strategies have recently been developed to overcome this immunosuppressive microenvironment.Combination therapies involving CPI aim at increasing tumor immunogenicity and promoting the recruitment and activation of effector T cells.Ongoing studies are therefore exploring the association of CPI with vaccines,oncolytic viruses,MEK inhibitors,cytokine inhibitors,and hypoxia-and stroma-targeting agents.Adoptive T-cell transfer is also under investigation.Moreover,translational studies on tumor tissue and blood,prior to and during treatment may lead to the identification of biomarkers with predictive value for both clinical outcome and response to immunotherapy. | Marc Hilmi Laurent Bartholin Cindy Neuzillet | 2018 | World Journal of Gastroenterology2018，24，20： | 6 |
| 2 | Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy显示文摘Advanced cholangiocarcinoma is associated with poor prognostic survival and has limited therapeutic options available at present. The importance of angiogenesis and expression of pro-angiogenic factors in intrahepatic forms of cholangiocarcinoma suggest that therapies targeting angiogenesis might be useful for the treatment of this disease. Here we report three cases of patients with advanced intrahepatic cholangiocarcinoma progressive after standard chemotherapy and treated with sunitinib 50 mg/d in 6-wk cycles of 4 wk on treatment followed by 2 wk off treatment(Schedule 4/2). In all three patients, sunitinib treatment was associated with a sustained disease control superior to 4 mo, patients achieving either a partial response or stable disease. A reduction in tumor size and density was observed in all cases, suggesting tumor necrosis as a result of sunitinib treatment in these patients. In addition, sunitinib was generally well tolerated and the occurrence of side effects was managed with standard medical interventions, as required. Our results suggest that sunitinib therapy maybe associated with favorable outcomes and tolerability in patients with advanced cholangiocarcinoma. Those observations contributed to launch a prospective phase Ⅱ multicenter trial investigating sunitinib in advanced intrahepatic cholangiocarcinoma(SUN-CK study; NCT01718327). | Chantal Dreyer Marie-Paule Sablin Mohamed Bouattour Cindy Neuzillet Maxime Ronot Safi Dokmak Jacques Belghiti Nathalie Guedj Valérie Paradis Eric Raymond Sandrine Faivre | 2015 | World Journal of Hepatology2015，7，6： | 4 |
| 3 | Stromal expression of SPARC in pancreatic adenocarcinoma显示文摘 | Cindy Neuzillet Annemila? Tijeras-Raballand Jér?me Cros Sandrine Faivre Pascal Hammel Eric Raymond | 2013 | Cancer and Metastasis Reviews (-)2013，，3： | 4 |
| 4 | FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts显示文摘AIM: To evaluate the efficacy and safety of the FOLFIRI regimen in patients with metastatic pancreatic adenocarcinoma (PAC) after the failure of gemcitabine and platinum salts. METHODS: All consecutive patients with histologically confirmed, metastatic PAC and World Health Organiza-tion performance status (PS) ≤ 2 received FOLFIRI-1 [irinotecan 180 mg/m2 on day 1 and leucovorin 400 mg/m2 followed by 5-fluorouracil (5-FU) 400 mg/m2 bolus, then 5-FU 2400 mg/m2 as a 46-h infusion, biweekly] or FOLFIRI-3 (irinotecan 100 mg/m2 on day 1 and leucovorin 400 mg/m2, then 5-FU 2400 mg/m2 as a 46-h infusion and irinotecan 100 mg/m2 repeated on day 3, biweekly) after failure of gemcitabine and platinum-based chemotherapies as a systematic policy in two institutions between January 2005 and May 2010. Tumor response, time to progression (TTP), overall survival rate (OS) and grade 3-4 toxicities were retrospectively studied. Subgroup analyses were performed to search for prognostic factors. RESULTS: Sixty-three patients (52.4% male, median age 59 years) were analyzed. Among them, 42.9% were PS 0, 38.1% were PS 1 and 19.0% were PS 2. Fifty one patients (81.0%) had liver metastases. Before the FOLFIRI regimen, patients had received 1 line (n = 19), 2 lines (n = 39) or 3 lines (n = 5) of chemotherapy. Median TTP obtained with the line before FOLFIRI was 3.9 mo (95% CI: 3.4-5.3 mo). A total of 480 cycles was completed (median: 6 cycles, range: 1-51 cycles). The main reason for discontinuing FOLFIRI was tumor progression (90.3%). Tumor control was achieved in 25 patients (39.7%) (partial response: n = 5, stable disease: n = 20) with FOLFIRI. Median TTP was 3.0 mo (95% CI: 2.1-3.9 mo) and median OS was 6.6 mo (95% CI: 5.3-8.1 mo). Dose adaptation was required in 36 patients (57.1%). Fifteen patients (23.8%) had grade 3-4 toxicities, mainly hematological (n = 11) or digestive (n = 4). Febrile neutropenia occurred in 3 patients. There was no toxic death. PS 2 was significantly associated with poor TTP [hazard ratio (HR): 16.036, P < 0.0001] and OS (HR: 4.003, P = 0.004). CONCLUSION: The FOLFIRI regimen had an acceptable toxicity and an interesting efficacy in our study, limited to patients in good condition (PS 0-1). | Cindy Neuzillet Olivia Hentic Benot Rousseau Vinciane Rebours Léla Bengrine-Lefèvre Franck Bonnetain Philippe Lévy Eric Raymond Philippe Ruszniewski Christophe Louvet Pascal Hammel | 2012 | World Journal of Gastroenterology2012，18，33： | 3 |
| 5 | Effects of the Molecular Weight of Peg Molecules (8, 20 and 35 KDA) on Cell Function and Allograft Survival Prolongation in Pancreatic Islets Transplantation显示文摘 | Y. Neuzillet S. Giraud L. Lagorce M. Eugene P. Debre F. Richard B. Barrou | 2006 | Transplantation Proceedings2006，，7： | 2 |
| 6 | A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer 显示文摘 | Neuzillet Y Paoletti X Ouerhani S | 2012 | PLoS ONE2012，7，48： | 1 |
| 7 | Long-term women-reported quality of life after radical eystectomy and orthotopie ileal neobladder reeonstruetion显示文摘 | Rouanne M Legrand G Neuzillet Y | 2014 | Ann Surg Oneol2014，21，4： | 1 |
| 8 | Study of urothelial bladder tumours in renal transplant recipients 显示文摘 | Neuzillet Y Cabaniols L Karam G | 2006 | Prog Urol2006，16，3： | 1 |
| 9 | Followup of renal oncoeytoma diagnosed by percutaneous tumor biopsy显示文摘 | Neuzillet Y Lechevallier E Andre M | 2005 | Urology2005，66，6： | 1 |
| 10 | Renal cell carcinoma(RCC)in patients with end-stage renal disease exhibits many favourable clinical,pathologic,and outcome features compared with RCC in the general population显示文摘 | Neuzillet Y Tillou T Mathieu R | 2011 | Eur Urol2011，60，2： | 1 |
| 11 | FOLFIRI regimen assecond-/third-line chemotherapy in patients with advanced pan-creatic adenocarcinoma refractory to gemcitabine and platinumsalts : A retrospective series of 70 patients 显示文摘 | Neuzillet C Hentic 0 Rousseau B | 2011 | J Clin Oncol2011，29，： | 1 |
| 12 | Follow-up of renaloncocytoma diagnosed by percutaneous tumor biopsy显示文摘 | Neuzillet Y Lechevallier E Andre M | 2005 | Urology2005，66，11： | 1 |
| 13 | Intrcldiverticular bladder tumours:Review of the Cancer Committee of the French Association of Urology显示文摘 | Neuzillet Y Comperat E Rouprêt M | 2012 | Prog Urol2012，22，9： | 1 |
| 14 | Perspectives of TGF-13 inhibition in pancreatic and hepatocellular carcinomas 显示文摘 | Neuzillet C de Gramont A Tijeras-Raballand A | 2014 | Oncotarget2014，5，1： | 1 |
| 15 | Intradiverticular bladder tumours: Review of the Cancer Committee of the French Association of Urology 显示文摘 | Neuzillet Y Comperat E Roupret M | 2012 | Prog Urol2012，22，9： | 1 |
| 16 | Endoscopic management of urothelial tumours of the upper urinary tract显示文摘 | TOMATIS L NEUZILLET Y CARCENAC A | 2006 | Prog Urol2006，16，2： | 1 |
| 17 | Accuracy and clinical role of fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 cm) renal masses显示文摘 | Neuzillet Y Lechevallier E Andre M | | 0，，： | 1 |
| 18 | Update on the different histological types of renal cell carcinoma and their specific treatment显示文摘 | Neuzillet y Rioux-Leclercq N Escudier B | 2011 | Prog Urol2011，21，2： | 1 |
| 19 | Followup of renal oncocytoma diagnosed by percutaneous tumor biopsy显示文摘 | Neuzillet Y Lechevallier E Andre M | 2005 | Urology2005，66，6： | 1 |
| 20 | Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review显示文摘At the time of diagnosis, 25% of patients with colorectal cancer(CRC) present with synchronous metastases, which are unresectable in the majority of patients. Whether primary tumor resection(PTR) followed by chemotherapy or immediate chemotherapy without PTR is the best therapeutic option in patients with asymptomatic CRC and unresectable metastases is a major issue, although unanswered to date. The aim of this study was to review all published data on whether PTR should be performed in patients with CRC and unresectable synchronous metastases. All aspects of the management of CRC were taken into account, es-pecially prognostic factors in patients with CRC and un-resectable metastases. The impact of PTR on survival and quality of life were reviewed, in addition to the characteristics of patients that could benefit from PTR and the possible underlying mechanisms. The risks of both approaches are reported. As no randomized study has been performed to date, we finally discussed how a therapeutic strategy's trial should be designed to pro-vide answer to this issue. | Louis de Mestier Gilles Manceau Cindy Neuzillet Jean Baptiste Bachet Jean Philippe Spano Reza Kianmanesh Jean Christophe Vaillant Olivier Bouché Laurent Han-noun Mehdi Karoui | 2014 | World Journal of Gastrointestinal Oncology2014，6，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员